According to a Wall Street Journal article, for the past few years the FDA has placed more emphasis on overseeing pharmaceutical products that are made in China. They have had trouble increasing the number of inspectors there, however, due to problems obtaining enough visas.
An agreement was reached with the Chinese government in late 2013 to expand regulatory activities there, the article said, and two subsequent agreements calling for closer regulatory cooperation were reached at the end of 2014. The FDA wanted to increase the number of inspectors in its Beijing office to 26; currently they have 10. Read the full WSJ story
